ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 100,80
0,11%
Dow Jones
39 671,04
-0,51%
DAX
18 711,72
0,16%
Brent Oil
82,355
1,01%
Bitcoin
69 723,15
0,90%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Canadá
  5. TSX
  6. ProMIS Neurosciences Inc (PMN)

  7. ProMIS Neurosciences Inc (PMN) Actualités

PMN

ProMIS Neurosciences (PMN)

ProMIS Neurosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:TSX:PMN
DateHeureSourceTitreSymboleSociété
18/04/202215h05PR Newswire (US)Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)TSX:PMNProMIS Neurosciences Inc
18/08/202114h15PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - PMNTSX:PMNProMIS Neurosciences Inc
18/08/202114h13PR Newswire (Canada)IIROC Trade Resumption - PMNTSX:PMNProMIS Neurosciences Inc
17/08/202122h53PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - PMNTSX:PMNProMIS Neurosciences Inc
17/08/202122h50PR Newswire (Canada)IIROC Trading Halt - PMNTSX:PMNProMIS Neurosciences Inc
18/11/201913h30PR Newswire (Canada)ProMIS Neurosciences Completes First Closing of Private PlacementTSX:PMNProMIS Neurosciences Inc
14/11/201913h30PR Newswire (Canada)ProMIS Neurosciences Announces Third Quarter 2019 ResultsTSX:PMNProMIS Neurosciences Inc
13/11/201913h30PR Newswire (Canada)ProMIS Neurosciences Undertaking $6.5M Private PlacementTSX:PMNProMIS Neurosciences Inc
07/11/201913h30PR Newswire (US)ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's diseaseTSX:PMNProMIS Neurosciences Inc
24/10/201909h00PR Newswire (US)ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's diseaseTSX:PMNProMIS Neurosciences Inc
23/10/201915h49PR Newswire (US)ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43TSX:PMNProMIS Neurosciences Inc
17/10/201913h30PR Newswire (US)ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tauTSX:PMNProMIS Neurosciences Inc
08/10/201913h30PR Newswire (US)ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System AtrophyTSX:PMNProMIS Neurosciences Inc
03/09/201913h30PR Newswire (US)ProMIS Neurosciences to Present at HC Wainwright Investment ConferenceTSX:PMNProMIS Neurosciences Inc
27/08/201913h30PR Newswire (Canada)ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom...TSX:PMNProMIS Neurosciences Inc
13/08/201913h30PR Newswire (Canada)ProMIS Neurosciences Announces Second Quarter 2019 ResultsTSX:PMNProMIS Neurosciences Inc
24/07/201913h30PR Newswire (Canada)ProMIS Neurosciences Announces Results of Annual Meeting of ShareholdersTSX:PMNProMIS Neurosciences Inc
18/07/201921h00PR Newswire (US)ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019TSX:PMNProMIS Neurosciences Inc
10/07/201913h30PR Newswire (Canada)ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International ConferenceTSX:PMNProMIS Neurosciences Inc
09/07/201913h30PR Newswire (US)ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific ReportsTSX:PMNProMIS Neurosciences Inc
27/06/201913h30PR Newswire (Canada)ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed AntibodiesTSX:PMNProMIS Neurosciences Inc
26/06/201913h30PR Newswire (Canada)ProMIS Neurosciences Closing Private PlacementTSX:PMNProMIS Neurosciences Inc
19/06/201913h30PR Newswire (US)ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory BoardTSX:PMNProMIS Neurosciences Inc
05/06/201913h30PR Newswire (US)ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific ConferenceTSX:PMNProMIS Neurosciences Inc
29/05/201913h30PR Newswire (US)ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative DiseasesTSX:PMNProMIS Neurosciences Inc
28/05/201913h30PR Newswire (US)ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of TauTSX:PMNProMIS Neurosciences Inc
14/05/201913h30PR Newswire (US)ProMIS Neurosciences Announces First Quarter 2019 ResultsTSX:PMNProMIS Neurosciences Inc
23/04/201913h30PR Newswire (US)ProMIS Neurosciences to Participate in the Think Equity Investor ConferenceTSX:PMNProMIS Neurosciences Inc
26/03/201912h30PR Newswire (US)ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019TSX:PMNProMIS Neurosciences Inc
21/03/201919h47PR Newswire (US)Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's DiseaseTSX:PMNProMIS Neurosciences Inc
 Showing the most relevant articles for your search:TSX:PMN

Dernières Valeurs Consultées

NASDAQ
AAXFHXX
Barclays Bank Plc Point ...
EU
BBPIY
Banco BPI SA Bond Mature...
BIT
P1WXG4
NLBNPIT1WXG4 20991231 10...
EU
FR2CIBFS3965
Credit Agricole CIB FCIA...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés